Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population

Charis Costopoulos, Azeem Latib, Toru Naganuma, Tadashi Miyazaki, Katsumasa Sato, Filippo Figini, Alessandro Sticchi, Mauro Carlino, Alaide Chieffo, Matteo Montorfano, Antonio Colombo

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objectives: To compare the early clinical outcomes between ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA) and cobalt chromium everolimus-eluting stents in real-world patients with mostly complex disease. Background: BVS represents the most interesting development in the drug-eluting stent field over recent years with promising results emerging from clinical trials. Available data however on the use of the ABSORB in real-world patients is limited. Methods: All patients (n = 92) treated with BVS and 1296 patients treated with EES were included in this study. Propensity score matching was performed to adjust for differences in baseline clinical characteristics, yielding 92 patient pairs (BVS = 92 patients with 137 lesions and EES = 92 patients with 124 lesions). Clinical outcomes were examined between the 2 groups at 6-months. Results: In both groups, most lesions were classified as either B2 or C (83.9% vs. 77.4%, P = 0.19). Predilatation (97.8% vs. 75.8%, P <0.01) as well as postdilation (99.3% vs. 77.4%, P <0.01) was more common in the BVS group. Clinical outcomes at 6-months were similar between the two groups with respect to both target lesion revascularization (3.3% vs. 5.4%, P = 0.41) and major adverse cardiac events (defined as the composite of target vessel revascularization, follow-up myocardial infraction and all-cause death) (3.3% vs. 7.6%, P = 0.19). Conclusions: ABSORB BVS for the treatment of complex lesions appears to be associated with good procedural and early clinical outcomes similar to those observed with conventional drug-eluting stents. Larger studies with long-term follow-up are required in order to fully assess the role of BVS in the treatment of such lesions and how this compares with that of conventional stents.

Original languageEnglish
Pages (from-to)E10-E15
JournalCatheterization and Cardiovascular Interventions
Volume85
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Stents
Blood Vessels
Population
Drug-Eluting Stents
Propensity Score
Everolimus
Chromium
Cobalt
Cause of Death
Clinical Trials
Therapeutics

Keywords

  • Bifurcation
  • Bioresorbable vascular scaffold
  • Clinical outcomes
  • Diffuse disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. / Costopoulos, Charis; Latib, Azeem; Naganuma, Toru; Miyazaki, Tadashi; Sato, Katsumasa; Figini, Filippo; Sticchi, Alessandro; Carlino, Mauro; Chieffo, Alaide; Montorfano, Matteo; Colombo, Antonio.

In: Catheterization and Cardiovascular Interventions, Vol. 85, No. 1, 01.01.2015, p. E10-E15.

Research output: Contribution to journalArticle

Costopoulos, Charis ; Latib, Azeem ; Naganuma, Toru ; Miyazaki, Tadashi ; Sato, Katsumasa ; Figini, Filippo ; Sticchi, Alessandro ; Carlino, Mauro ; Chieffo, Alaide ; Montorfano, Matteo ; Colombo, Antonio. / Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. In: Catheterization and Cardiovascular Interventions. 2015 ; Vol. 85, No. 1. pp. E10-E15.
@article{f5462dd49d874cb183ef862f23a9bc9e,
title = "Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population",
abstract = "Objectives: To compare the early clinical outcomes between ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA) and cobalt chromium everolimus-eluting stents in real-world patients with mostly complex disease. Background: BVS represents the most interesting development in the drug-eluting stent field over recent years with promising results emerging from clinical trials. Available data however on the use of the ABSORB in real-world patients is limited. Methods: All patients (n = 92) treated with BVS and 1296 patients treated with EES were included in this study. Propensity score matching was performed to adjust for differences in baseline clinical characteristics, yielding 92 patient pairs (BVS = 92 patients with 137 lesions and EES = 92 patients with 124 lesions). Clinical outcomes were examined between the 2 groups at 6-months. Results: In both groups, most lesions were classified as either B2 or C (83.9{\%} vs. 77.4{\%}, P = 0.19). Predilatation (97.8{\%} vs. 75.8{\%}, P <0.01) as well as postdilation (99.3{\%} vs. 77.4{\%}, P <0.01) was more common in the BVS group. Clinical outcomes at 6-months were similar between the two groups with respect to both target lesion revascularization (3.3{\%} vs. 5.4{\%}, P = 0.41) and major adverse cardiac events (defined as the composite of target vessel revascularization, follow-up myocardial infraction and all-cause death) (3.3{\%} vs. 7.6{\%}, P = 0.19). Conclusions: ABSORB BVS for the treatment of complex lesions appears to be associated with good procedural and early clinical outcomes similar to those observed with conventional drug-eluting stents. Larger studies with long-term follow-up are required in order to fully assess the role of BVS in the treatment of such lesions and how this compares with that of conventional stents.",
keywords = "Bifurcation, Bioresorbable vascular scaffold, Clinical outcomes, Diffuse disease",
author = "Charis Costopoulos and Azeem Latib and Toru Naganuma and Tadashi Miyazaki and Katsumasa Sato and Filippo Figini and Alessandro Sticchi and Mauro Carlino and Alaide Chieffo and Matteo Montorfano and Antonio Colombo",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ccd.25569",
language = "English",
volume = "85",
pages = "E10--E15",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population

AU - Costopoulos, Charis

AU - Latib, Azeem

AU - Naganuma, Toru

AU - Miyazaki, Tadashi

AU - Sato, Katsumasa

AU - Figini, Filippo

AU - Sticchi, Alessandro

AU - Carlino, Mauro

AU - Chieffo, Alaide

AU - Montorfano, Matteo

AU - Colombo, Antonio

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: To compare the early clinical outcomes between ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA) and cobalt chromium everolimus-eluting stents in real-world patients with mostly complex disease. Background: BVS represents the most interesting development in the drug-eluting stent field over recent years with promising results emerging from clinical trials. Available data however on the use of the ABSORB in real-world patients is limited. Methods: All patients (n = 92) treated with BVS and 1296 patients treated with EES were included in this study. Propensity score matching was performed to adjust for differences in baseline clinical characteristics, yielding 92 patient pairs (BVS = 92 patients with 137 lesions and EES = 92 patients with 124 lesions). Clinical outcomes were examined between the 2 groups at 6-months. Results: In both groups, most lesions were classified as either B2 or C (83.9% vs. 77.4%, P = 0.19). Predilatation (97.8% vs. 75.8%, P <0.01) as well as postdilation (99.3% vs. 77.4%, P <0.01) was more common in the BVS group. Clinical outcomes at 6-months were similar between the two groups with respect to both target lesion revascularization (3.3% vs. 5.4%, P = 0.41) and major adverse cardiac events (defined as the composite of target vessel revascularization, follow-up myocardial infraction and all-cause death) (3.3% vs. 7.6%, P = 0.19). Conclusions: ABSORB BVS for the treatment of complex lesions appears to be associated with good procedural and early clinical outcomes similar to those observed with conventional drug-eluting stents. Larger studies with long-term follow-up are required in order to fully assess the role of BVS in the treatment of such lesions and how this compares with that of conventional stents.

AB - Objectives: To compare the early clinical outcomes between ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA) and cobalt chromium everolimus-eluting stents in real-world patients with mostly complex disease. Background: BVS represents the most interesting development in the drug-eluting stent field over recent years with promising results emerging from clinical trials. Available data however on the use of the ABSORB in real-world patients is limited. Methods: All patients (n = 92) treated with BVS and 1296 patients treated with EES were included in this study. Propensity score matching was performed to adjust for differences in baseline clinical characteristics, yielding 92 patient pairs (BVS = 92 patients with 137 lesions and EES = 92 patients with 124 lesions). Clinical outcomes were examined between the 2 groups at 6-months. Results: In both groups, most lesions were classified as either B2 or C (83.9% vs. 77.4%, P = 0.19). Predilatation (97.8% vs. 75.8%, P <0.01) as well as postdilation (99.3% vs. 77.4%, P <0.01) was more common in the BVS group. Clinical outcomes at 6-months were similar between the two groups with respect to both target lesion revascularization (3.3% vs. 5.4%, P = 0.41) and major adverse cardiac events (defined as the composite of target vessel revascularization, follow-up myocardial infraction and all-cause death) (3.3% vs. 7.6%, P = 0.19). Conclusions: ABSORB BVS for the treatment of complex lesions appears to be associated with good procedural and early clinical outcomes similar to those observed with conventional drug-eluting stents. Larger studies with long-term follow-up are required in order to fully assess the role of BVS in the treatment of such lesions and how this compares with that of conventional stents.

KW - Bifurcation

KW - Bioresorbable vascular scaffold

KW - Clinical outcomes

KW - Diffuse disease

UR - http://www.scopus.com/inward/record.url?scp=84923229471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923229471&partnerID=8YFLogxK

U2 - 10.1002/ccd.25569

DO - 10.1002/ccd.25569

M3 - Article

VL - 85

SP - E10-E15

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -